Friday 6 November 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024.
- Revenue
- +13.0%
- EPS
- +21.1%
- Free cash flow
- +77.7%
- Total debt
- +7.63%
Quarter to September 2026, against a year earlier
6.86
0.06
+0.88%
Follow EOLS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 3 |
+8 more TTM periods Free account |
| 93.47% | 138.57% | 245.43% | 587.36% | ||
| (12.38%) | (14.40%) | (20.01%) | (22.53%) | ||
ROIC |
(12.60%) | (14.47%) | (19.54%) | (29.51%) | |
Return on Tangible Assets |
(48.46%) | (46.48%) | (56.96%) | (70.76%) | |
Average Days of Receivables |
67.60 | 71.95 | 63.16 | 67.18 | |
Free Cash Flow per Share |
(0.13) | (0.33) | (0.69) | (0.79) | |
Free Cash Flow |
(8.82) | (21.90) | (44.87) | (50.72) | |
Capital Expenditures |
(6.17) | (6.51) | (8.28) | (8.45) | |
| Other line items | |||||
Cash ROIC |
(5.48%) | (12.80%) | (25.29%) | (28.68%) | |
Accounts Receivable Turnover |
5.88 | 5.75 | 6.06 | 5.81 | |
Accounts Payable Turnover |
2.01 | 3.11 | 5.74 | 6.14 | |
Inventory Turnover |
1.89 | 3.13 | 5.88 | 5.12 | |
Average Days of Payables |
287.51 | 154.21 | 69.58 | 85.21 | |
Days of Inventory on Hand |
276.22 | 141.79 | 88.35 | 98.35 | |
Tax Rate |
0.03 | 0.02 | 0.02 | 0.01 | |
Research and Development Expense of Revenue |
2.94% | 3.05% | 3.18% | 3.22% | |
Selling, General and Administrative Expense of Revenue |
66.55% | 68.41% | 71.61% | 74.29% | |
Share Based Compensation of Revenue |
6.60% | 6.64% | 6.59% | 6.96% | |
Interest Coverage |
(0.95) | (1.15) | (1.26) | (1.66) | |
Operating CF/Net income |
0.09 | 0.45 | 0.84 | 0.82 | |
Depreciation/Fixed assets |
2.57 | 2.32 | 2.05 | 1.87 | |
Capex/Depreciation |
(0.49) | (0.56) | (0.76) | (0.84) | |
Revenue per Share |
4.93 | 4.80 | 4.63 | 4.61 | |
Operating CF per Share |
(0.04) | (0.23) | (0.56) | (0.66) | |
Capex per Share |
(0.09) | (0.10) | (0.13) | (0.13) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026